Does major pathological response after neoadjuvant Immunotherapy in resectable non-small-cell lung cancers predict prognosis? a systematic review and meta-analysis.
Yujia ChenJianjun QinYajing WuQiang LinJianing WangWei ZhangFei LiangZhouguang HuiMin ZhaoJun WangPublished in: International journal of surgery (London, England) (2023)
The findings of this meta-analysis suggest that neoadjuvant chemo-immunotherapy achieved higher MPR in NSCLC patients，and increased MPR might be associated with survival benefits treated with neoadjuvant immunotherapy. It appears that the MPR may serve as a surrogate endpoint of survival to evaluate neoadjuvant immunotherapy.
Keyphrases
- locally advanced
- rectal cancer
- lymph node
- systematic review
- squamous cell carcinoma
- end stage renal disease
- radiation therapy
- newly diagnosed
- small cell lung cancer
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- cell therapy
- randomized controlled trial
- free survival
- meta analyses
- patient reported outcomes
- young adults
- cancer therapy
- advanced non small cell lung cancer
- liver metastases